Given that metabolic syndrome and glucose dysregulation are established risk factors and exacerbators of AD pathology, it is imperative to rigorously assess the long-term metabolic consequences of S6K1-targeted therapies. Here, RPS6KB1 is linked to Alzheimer disease.